PMID- 35142581
OWN - NLM
STAT- MEDLINE
DCOM- 20220712
LR  - 20220726
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 63
IP  - 7
DP  - 2022 Jul
TI  - Gender disparities in the National Institutes of Health funding for hematologic 
      malignancies and cellular therapies.
PG  - 1708-1713
LID - 10.1080/10428194.2022.2038378 [doi]
AB  - We investigated gender inequality in the National Institutes of Health (NIH) 
      funding for hematologic malignancies and cellular therapies (HMCT). The data were 
      retrieved from the NIH Research Portfolio Online Reporting Tools (RePORT). In 
      2018-2019, 1834 grants totaling $799 million were awarded (men 71% vs. women 29%) 
      to 975 principal investigators (PIs), including 680 (70%) male PIs and 295 (30%) 
      female PIs. There was no significant gender difference in the mean grant amount 
      per PI. Male PIs as compared to female PIs had a higher h-index (44 vs 31, 
      p < 0.001), a higher number of publications (159.5 vs 94, p < 0.001), and higher 
      years of active research (26 vs 21, p < 0.001). In multivariate analyses, a 
      higher h-index independently predicted a higher mean grant amount per PI 
      (p = 0.010), and female PIs were independently less likely to have a higher 
      h-index (p < 0.001). Our study shows significant gender disparity in the NIH 
      funding for HMCT research.
FAU - Siddiqui, Raheel Sufian
AU  - Siddiqui RS
AUID- ORCID: 0000-0002-7284-4435
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
AD  - Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/New York 
      City Health and Hospitals/Queens, Jamaica, NY, USA.
FAU - Chaudhary, Sibgha Gull
AU  - Chaudhary SG
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Shahzad, Moazzam
AU  - Shahzad M
AUID- ORCID: 0000-0002-9609-6160
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
AD  - Department of Medicine, St Mary's Medical Center, Huntington, WV, USA.
FAU - Anwar, Iqra
AU  - Anwar I
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Hussain, Ali
AU  - Hussain A
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Ahmed, Nausheen
AU  - Ahmed N
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Abhyankar, Sunil Hari
AU  - Abhyankar SH
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Shune, Leyla
AU  - Shune L
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Hematti, Peiman
AU  - Hematti P
AD  - Division of Hematology/Oncology, University of Wisconsin School of Medicine & 
      Public Health, Madison, WI, USA.
FAU - Male, Heather
AU  - Male H
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Khosa, Faisal
AU  - Khosa F
AD  - Department of Radiology, University of British Columbia, Vancouver, Canada.
FAU - Lin, Tara
AU  - Lin T
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - McGuirk, Joseph Patrick
AU  - McGuirk JP
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
FAU - Callander, Natalie Scott
AU  - Callander NS
AD  - Division of Hematology/Oncology, University of Wisconsin School of Medicine & 
      Public Health, Madison, WI, USA.
FAU - Mushtaq, Muhammad Umair
AU  - Mushtaq MU
AUID- ORCID: 0000-0001-8122-0563
AD  - Division of Hematologic Malignancies and Cellular Therapeutics, University of 
      Kansas Medical Center, Kansas City, KS, USA.
LA  - eng
PT  - Journal Article
DEP - 20220210
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - *Biomedical Research
MH  - Female
MH  - *Hematologic Neoplasms/diagnosis/epidemiology/therapy
MH  - Humans
MH  - Male
MH  - National Institutes of Health (U.S.)
MH  - Sex Factors
MH  - United States/epidemiology
OTO - NOTNLM
OT  - Hematologic malignancies
OT  - cellular therapies
OT  - gender disparities
OT  - research funding
EDAT- 2022/02/11 06:00
MHDA- 2022/07/14 06:00
CRDT- 2022/02/10 12:13
PHST- 2022/02/11 06:00 [pubmed]
PHST- 2022/07/14 06:00 [medline]
PHST- 2022/02/10 12:13 [entrez]
AID - 10.1080/10428194.2022.2038378 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2022 Jul;63(7):1708-1713. doi: 10.1080/10428194.2022.2038378. Epub 
      2022 Feb 10.